Skip Navigation LinksHome > January 2012 - Volume 112 - Issue 1 > Eculizumab (Soliris) Receives Approval for a New Indication
AJN, American Journal of Nursing:
doi: 10.1097/01.NAJ.0000410356.41652.0d
Drug Watch

Eculizumab (Soliris) Receives Approval for a New Indication

Aschenbrenner, Diane S. MS, RN

Collapse Box


* Eculizumab (Soliris) is now approved to treat the rare blood disorder atypical hemolytic uremic syndrome in adults and children.

* Common adverse effects include hypertension, diarrhea, headache, anemia, vomiting, nausea, upper respiratory infection, urinary tract infection, and leukopenia.

* Eculizumab's label carries a warning that the drug increases the risk of life-threatening meningococcal infection. Nurses should confirm that vaccination against meningococcal infection occurred at least two weeks before patients start therapy with eculizumab.

© 2012 Lippincott Williams & Wilkins, Inc.


Article Tools


Article Level Metrics